Kolluri et al. considered that AhR may be a drug target for cancer [11], and AhR inhibitors can synergize with a immunotherapeutic treatment (anti-PD-L1 antibody) to enhance antitumor activity in the mouse model of lung cancer [32]. Here, AHR is linked to lung cancer.